Evan Seigerman
Stock Analyst at BMO Capital
(0.78)
# 3,638
Out of 4,829 analysts
141
Total ratings
37.5%
Success rate
-16.21%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $120.42 | -4.50% | 15 | May 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $124.25 | +11.87% | 26 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $110 → $115 | $104.44 | +10.11% | 15 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $566 → $520 | $440.38 | +18.08% | 14 | Dec 20, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $48.33 | +26.23% | 11 | Nov 12, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $61.28 | -15.14% | 12 | Oct 30, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $760.12 | +44.85% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $47.12 | +48.56% | 5 | Jun 17, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $25.33 | +57.95% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $7.96 | +402.51% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $573.96 | +37.29% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.14 | +16.82% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $275.58 | -11.82% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.11 | +134.83% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $23.05 | +160.30% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.18 | +2,188.14% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.60 | +1,775.00% | 3 | May 12, 2020 |
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $120.42
Upside: -4.50%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $124.25
Upside: +11.87%
Gilead Sciences
Feb 12, 2025
Maintains: Outperform
Price Target: $110 → $115
Current: $104.44
Upside: +10.11%
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Outperform
Price Target: $566 → $520
Current: $440.38
Upside: +18.08%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $48.33
Upside: +26.23%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $61.28
Upside: -15.14%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $760.12
Upside: +44.85%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $47.12
Upside: +48.56%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $25.33
Upside: +57.95%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $7.96
Upside: +402.51%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $573.96
Upside: +37.29%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.14
Upside: +16.82%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $275.58
Upside: -11.82%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.11
Upside: +134.83%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $23.05
Upside: +160.30%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.18
Upside: +2,188.14%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.60
Upside: +1,775.00%